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Principal Investigator/Program Director (Last, first, middle): Zalkow, Leon H. 
B. METHODOLOGICAL CONSIDERATIONS 
The techniques described in the original grant for the biochemical and behavioral 
characterization of the synthesized compounds will be retained, except that [3H] CFT instead of 
[
3H]methylphenidate binding will be used to characterize the activity of the potential cocaine 
antagonists at the stimulant receptor. Due to its higher affinity and slower dissociation rate compared 
to cocaine43, [ 3H]CFT has become a popular radioligand for the characterization of the cocaine 
receptor on the dopamine transporter. [3H]methylphenidate binds to a closely related stimulant binding 
site, but its relatively low affinity (K0 _ 1 00 nM) and rapid dissociation rate
8 have led to its 
discontinuation as a commercially available radioligand. We feel that use of [3H]CFT in these studies 
will better facilitate comparison of the data generated here with that from other laboratories. Because 
the two probes may bind to slightly different sites on the transporter (see discussion of the effect of 
sulfhydryl reagents on stimulant binding, above), however, determination of the inhibition of _ 
[
3H]methylphenidate binding by compounds found to antagonize the behavioral effects of cocaine in 
these studies may eventually be desirable. 
3. PROGRESS REPORT/PRELIMINARY STUDIES 
A. LIST OF ALL PERSONNEL 
Name Title Birthday SS No. Dates of service %time 
Deutsch,HM Senior Research Sci. 4-23-40 119-32-5569 12-90 to present 50-75 
Zalkow,LH Regents' Professor 11-27-29 255-36-9515 12-90 to present 8 
Kowalik, EG Research Scientist 8-6-51 450-55-0969 12-90 to 11-91 83 
Hernandez, M Postdoctoral Fellow 5-1-55 382-62-3549 12-90 to 11-91 21 
Lee, H Graduate Student 12-25-65 172-54-4934 12-90to 11-91 79 
Sepcic, K Graduate Student 12-6-67 247-49-9411 11-91 to 6-92 100 
Huang, F-Y Postdoctoral Fellow 2-26-'56 004-80-2054 11-91 to 6-92 80 
Bharathi, S Postdoctoral Fellow 5-10-54 509-96-3189 11-91 to 3-92 100 
Li, L Technician 11-13-56 368-11-5346 5-92 to 6-92 50 
Schweri, M Associate Professor 8-29-46 404-60-6486 12-90 to 6-92 40 
Cassidy, M Research Technician 10-20-42 436-68-3042 12-90 to 4-92 100 
B. PREVIOUS SPECIFIC AIMS. 
The purpose of the previously proposed work was to synthesize compounds which would 
antagonize the reinforcing and psychosis-inducing properties of cocaine and other stimulants by 
binding irreversibly to sites on or related to the dopamine transporter. This approach was based on 
previous findings that Metaphit, a compound which in vitro irreversibly inhibits binding to recognition 
sites for the stimulant drugs cocaine and methylphenidate and irreversibly blocks dopamine transport, 
prevents the increased locomotor behavior normally seen following the administration of cocaine and 
other compounds belonging to the methylphenidate class of stimulant drugs. 
Confirmation of this hypothesis would be sought by testing the drug Fourphit, which is known 
to bind irreversibly to the stimulant binding site, but not to the phencyclidine binding site. The 
compounds selected for modification were mazindol, the ·GaR· series of aryl 
1 ,4-dialk(en)ylpiperazines, methylphenidate, and dopamine itself. The reactive groups to be introduced 
into their structures were isothiocyanate, bromoacetamide, maleimide, and fluorosulfonyl. 
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The ability of the newly synthesized compounds to irreversibly block the actions of cocaine and 
other stimulants at the dopamine transporter would be tested by examining their behavior in the 
[
3H]methylphenidate radioreceptor assay. The compounds would also be tested in vitro for their ability 
to irreversibly block [3H]dopamine uptake. 
Those compounds which were found to irreversibly inhibit stimulant binding and dopamine 
uptake with some degree of selectivity would then be tested in vivo for their behavioral effect~. 
Activity of the compounds would be examined in three separate behavioral paradigms. Compounds 
which showed behavioral activity would then be tested ex vivo for their ability to block 
[
3H]methylphenidate binding and [3H]dopamine uptake. 
C. SUMMARY OF RESULTS LEADING TO PROGRESS TOWARDS THE SPECIFIC AIMS. 
1. Foumhit 
a. Biochemical studies. 
i. In vitro. Studies examining the effect of Fourphit on [3H]methylphenidate 
binding8 showed that this isothiocyanate derivative of phencyclidine inhibited binding to the stimulant 
recognition site with an IC50 of 7.1 pM. Washout studies (conducted under conditions where reversibly 
bound phencyclidine was completely removed) demonstrated that inactivation of the stimulant 
recognition site by Fourphit was irreversible, while inactivation of the phencyclidine receptor by the 
compound was reversible. Partial protection of the stimulant recognition site from inactivation by 
Fourphit was afforded by pretreatment of striatal tissue with saturating amounts of unlabeled 
methylphenidate, suggesting that the acylating compound may bind covalently to the receptor directly 
at the site recognized by methylphenidate, rather than allosterically. Studies examining the effects of 
Fourphit on the dissociation rate of [3H]methylphenidate also supported the interpretation that the 
inhibition caused by Fourphit was not due to an allosteric interaction of the compound with the 
stimulant recognition site. 
ii. Ex vivo. Measurement of [3H]methylphenidate binding in striatal tissue 
dissected from the rats utilized in the behavioral studies described below revealed no consistent 
changes supportive of altered dopamine transport function. _ 
b. Behavioral studies. As predicted in the original proposal, Fourphit attenuated the 
hyperactivity induced by challenge with a low dose of cocaine 7• Intravenous injection of Fourphit (20 
mg/kg) had little effect on the activity levels of rats. The effect of Fourphit on stimulant-induced 
locomotion appeared to vary with the respective stimulants. Rats pretreated with Fourphit prior to 
challenge with methylphenidate (Ritalin), which belongs to the same class of stimulant agents as 
cocaine, however, showed no change (or possibly even a slight increase) in activity, compared to 
vehicle-pretreated control animals injected with methylphenidate. Pretreatment with Fourphit 
significantly increased locomotor activity observed following low doses of d-amphetamine (0.8 and 
1.25 mg/kg, respectively), while it was without effect on the activation induced by 1.5 mg/kg of 
methamphetamine, which belongs to the same class of stimulant drugs as amphetamine. 
In conclusion, the results with fourphit generally support our hypothesis that drugs that bind 
irreversibly to the stimulant binding sites can act as antagonists to cocaine. 
2. GBR Series 
a. Synthesis CScheme 1 )1 • The reaction of piperazine with cinnamyl bromide gave both 
the desired compound 1 as well as the dialkylated material 4 which can be separated by distillation. 
Amine 1 was then alkylated with chloroether 2, which was made by reduction of the corresponding 
benzophenone followed by etherification with chloroethanol. Selective reduction of the nitro group of 
3a or 3b yielded the amines 3c or 3d which served as the basic starting materials for the synthesis of 
the potential irreversible compounds. lsothiocyanates 3e and 3f and maleimides 3g and 3h were 
prepared by standard methods. Using a similar method, but starting with fluoreneone, compound 5 
was synthesized. 
After the synthesis of the 3' -amino derivative 6b had been initiated (by the scheme shown), 
we learned that colleagues at NIH (K. Rice and B. deCosta) had already made this compound. Using 
material supplied by them, the synthesis of 6c and 6d was completed. 
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b. Pharmacology. 
i. Binding studies 
a. In vitro studies. The parent compound (GBR-12783) and synthetic 
compounds 3-6 were tested in the [3H]methylphenidate binding assay (Table 1 )1 • The inhibition was 
marked by an apparent Hill coefficient greater than one in all cases. Washout studies using a sodium-
free solution for removing reversibly-bound compounds showed that compounds 3e and 3f bound 
irreversibly to the stimulant recognition site, whereas 3g showed partial irreversible inhibition and all of 
the other tested compounds were reversible. The time course for the reaction of 3f with the 
[
3H]methylphenidate binding site was found to be extremely rapid, even at 0 °C. Scatchard analysis of 
the effect of 3f on [3H]methylphenidate binding suggest that the compound leads to a reduction in 
Bmu· Protection of the site from irreversible inhibition by 3f using saturating amounts of GBR-12783 
was attempted. Complete protection using this technique was not observed. 
TABLE 1. 
Inhibition of [3H]methylphenidate binding by GBR-12783 and its derivatives 
Compound l~(nM) Hill Compound IC60(nM) Hill 
Coefficient Coefficient 
GBR-12783 12.0 ± 1.2 3.03 ± 0.05 3f 493 ± 94 2.30 ± 0.13 
3a 11.9 ± 1.2 1.55 ± 0.12 3g 970 ± 46 1.32 ± 0.18 
3b 39.3 ± 4.7 1.56 ± 0.13 3h 1700 ± 412 1.90 ± 0.29 
3c 15.8 ± 1.3 1.89 ± 0.06 4 2000 NO 
3d 15.4 ± 0.9 1.89 ± 0.05 5 1700 NO 
3e 283 ± 18 1.51 ± 0.08 6b 48 NO 
b. Ex vivo studies. [3H]methylphenidate binding studies were conducted 
on the striatal tissue of the rats used in the behavioral studies summarized below. The rats were 
sacrificed shortly after the termination of each behavioral experiment, the tissue was removed and 
frozen until the series was completed, at which time all the samples were analyzed using the same 
radioreceptor assay. No reduction in [3H]methylphenidate binding was observed as a function of 
treatment. However, further statistical analysis of one experimental series suggested a negative 
correlation between binding and activity of the individual rats treated with 3e, while rats treated with 
vehicle in the same experiment showed a possible positive correlation between binding and activity. 
ii. l3Hl Dopamine transoort studies. The potency of test compounds in inhibiting 
[
3H]dopamine transport into striatal synaptosomes was assessed. IC50's shown below are derived from 
inhibition curves in which inhibition at five to seven different concentrations of test compound was 
determined. The time course for inactivation of [3H]dopamine transport by 3f has been examined and 











iii. Behavioral studies. The effects of 3e and 3f on the hyperactivity caused by low dose 
cocaine and amphetamine were examined and these results are summarized in Table 2 (Fourphit and 
mazindol derivative 11 d are included in this table for convenience). Despite solubility problems with 
some of these compounds which limited the amount of drug which could be delivered by certain 
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routes, some interesting results were ob~ained. The test compounds were delivered by intravenous 
and intraperitoneal injection, as well as microinjection directly into the nucleus accumbens. In some 
experimental paradigms, 3e and 3f potentiated the effects of low dose cocaine; no conditions were 
found in which it blocked cocaine's behavioral effects. Compound 3e was ineffective in preventing the 











P~~o""'--N~-H + ~COCI l)h .. 
\._J )=::=./ I or g on 6b 
02N gives 6c or 6d · 





a. K2C03, EtOH; b. NaBH4 , EtOH; c. HOCH2CH2CI, H2S04 ; d. K2C03, Kl, CH3CO-iBu, heat; 
e. NaBH" • 3S, THF, /1; f. CSCI2/HCCI3, NaHC03/H20; g. 1) maleic anhydride, THF 2) NaOAc, Ac20; h. 
pyridine as solvent gives 6a; condition (e), followed by liAIH 4 gives 6b. 
In summary, there was no evidence that irreversible binding GBR-Iike compounds could act as 
antagonists to cocaine. However, the 3'-isothiocyanate and maleimide (6c and 6d) have not yet been 
tested. lsothiocyanate groups at the meta- or para- position led to a 20- and 40-fold reduction in 
binding potency, respectively whereas maleimido groups at these positions led to 80- and 140-fold 
reductions in binding potency, respectively. Both the 3- and 4-amino and nitro-substituted 
intermediates showed only small decreases in binding potency, compared to the parent compound. 
Since the nitro group is strongly electron withdrawing and the amino group is strongly electron 
releasing, this indicated that electronic factors are only of minimal importance. The marked decrease in 
binding potency for the bulkier maleimide and isothiocyanate groups indicate that steric factors appear 
to dominate. This is also confirmed by the low binding potency of the restricted rotation analog 5. In 
fact, since the IC50 value for 3h is appoximately the same as that for both 4 and 5 it appears that the 
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4-maleimide group essentially blocks the binding at this end of the molecule. Since these are racemic 
compounds this implies that both phenyl rings comprising the geminal diphenyl portion of the molecule 
(see structure 3) are involved in the binding interaction. If this were not true, then we would expect 
one of the isomers (of the d,l pair) to have a binding potency similar to the unsubstituted compound 
(GBR-12783) and therefore the racemic mixture would have no more than a two-fold reduction in 
binding potency. The washout conditions used to evaluate the irreversibility of the inhibition of 
[
3H]methylphenidate binding by these compounds led to the complete removal of reversibly bound 
inhibitors only when potassium chloride was substituted for sodium chloride in the wash solution. 
Table 2. Summary of the effects of test compounds on stimulant-induced hyperactivity. 
TEST DOSE CHALLENGED 
COMPOUND (mg/Kg) ROUTE WITH: AT(HRS) SEX RESULTS 
FOURPHIT 20 IV COCAINE 24 F • 
3e 2 IV COCAINE 24 M .. 
3e 2 IV COCAINE 0.5 M t 
3e 7.6 nmols intra- · COCAINE 24 M .. 
accumbens 
3e 2 IV D-AMPHET 24 M .. 
3f 2 IV COCAINE 24 M c. 
3f 2 IV COCAINE 0.5 M c. 
3f 25 IP COCAINE 24 M t 
3f(NBR 25 IP COCAINE 24 M .. 
RATS) 
11d 1.25 IV COCAINE 0.25 M .. 
Cocaine dose was 15 mg/kg, i.p., as the hydrochloride salt. All studies done in sprague-Dawley rats, 
except where noted. Rats were challenged with stimulant at the time shown in hours after injection 
with the test compound. Activity was compared to rats injected with vehicle instead of test 
compound, before challenge with the stimulant. Results show change in activity with respect to 
stimulant injected controls ( U, decrease;•, no change; t, increase). Six to eight rats were in each 
treatment group. 
3. Mazindol Series 
a. Synthesis (Scheme 2). The Friedei-Crafts acylation of chlorobenzene with 
4-nitrophthalic anhydride gave a 4: 1 ratio of the 5-nitro product (7a) to the 4-nitro product (7b), which 
could be separated by several methods. Condensation of 7a with ethylene diamine followed by 
catalytic reduction gave 8. Lithium aluminum hydride reduction did not give the expected product; 
iostead a material formulated as 9 was produced which could not be converted to a mazindol. 
However, the synthesis of both mazindol ( 11 c) and the ring expanded product 11 d was accomplished 
using this method. 
A new methodology, based on work in the patent literature started with 7a and the 
monotosylate of ethylenediamine. Compound 10 could be converted to nitromazindol (11a) in good 
yield as indicated below. Catalytic reduction of 11a to 11b, without reduction of the carbon-nitrogen 
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double bound, appeared to be successful although a pure product has not yet been isolated. We are 


























lla R=N02, n=2 




a. Chlorobenzene, AICI3; b. Ethylenediamine, toluene, heat (remove water); c. H2/Pd d. LiAIH4/Et20; e. 
Cone. H2S04 , 70 °C. 
b. Pharmacology. 
i. Binding studies. 
Comoound 







ii. Behavioral studies. Since the mazindol derivative 11d (with an expanded 
imidazole ring) had been reported earlier to have high binding potency, but no behavioral effect (and 
thus a potential antagonist), its influence on the hyperactivity caused by low dose cocaine were 
examined. The results are summarized in the table 1 , and show no effect on cocaine induced behavior. 
In summary, the synthesis of irreversible mazindol derivatives is nearing completion at this 
time. Although the nitro compound 11a shows greatly reduced binding potency, this may be due to 
electronic factors that would not be present in the amino compound. Interestingly, the ring expanded 
mazindol 11 d shows increased binding potency, but no behavioral effects. 
4. Methylphenidate Series 
a. Synthesis (Scheme 3). The reaction of p-methoxyphenylacetonitrile with 
2-bromopyridine according to a literature procedure gave a difficult to separate mixture from which the 
desired product ( 12) could be separated only by chromatography in very low yield. After modification 
of the conditions, satisfactory yields (isolated by crystallization) were obtained as shown below. 
Partial hydrolysis of 12 gave an amide which upon hydrogenation gave 13 as a mixture of erythro 
(predominately) and threo isomers. Deprotection and isomerization of mixture 13 was achieved in 
excellent yield using 48% HBr which yielded 14, in which the predominant threo isomer could be 
separated by crystallization. Conversion of threo 14 to the methyl ester yielded 
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p-hydroxymethylphenidate ( 15a). In order to prevent problems with the synthesis of potential 
irreversibly binding compounds, the synthesis of N-methyl p-hydroxymethylphenidate was attempted. 
Reductive amination (with formaldehyde and sodium cyanoborohydride) gave a mixture of products in 
low yield which could not be separated (may have been an erythro/threo mixture). Clark-Eschweiler 
conditions gave a mixture from which the N-methyl compound ( 15b) and the bis-hydroxymethyl 
compound ( 15c) could be isolated. 
The ethyl ester of male imido B-alanine ethyl ester ( 16a) has been synthesized and it has been 
hydrolyzed to the free acid 16b. Current work involves coupling 16b to the protected compound 15d, 









15a R1=H, R2=R3=H 15b R1=H, R2=H, R3=CH3 15c R1=CH20H, R2=CH20H, R3=CH3 
15d R1=H, R2=H, R3=t-BOC 15e R1=maleimido-~-alanyl, R2=R3=H 
a. t-BuOK, toluene, 2-bromopyridine; b. Pt/H0Ac/H2 ; c. cone. H2S04 ; d. 48% HBr; e. MeOH/HCI 
b. Pharmacology 











In summary, it has been shown that some substituents in the para or meta position of the 
benzene ring of methylphenidate do not significantly affect binding affinity, whereas an N-methyl 
substituent leads to an appproximate 1 O-f old lowering of affinity. 
5. Dopamine series 
a. Synthesis (Scheme 4). The benzylation and subsequent hydrolysis of 
dihydroxyphenylacetic acid yielded the protected acid in relatively low yield. Reduction of the acid and 
formation of the chloride 17 proceeded smoothly as did the subsequent alkylation to form diamines 
18a-c and after deprotection catechols 19a-c. Bromoacetamide derivative 18d was readily synthesized 
and purified; although 19d has been made, a pure product has yet to be isolated. 
b. Pharmacology. Washout studies showed that the bromoacetamide 18d irreversibly 
inhibits binding, while the unprotected precursor '9a does not. Surprisingly, 18a (which has no 
reactive group) also appeared to irreversibly inhibit binding, even under conditions• shown to 
effectively remove •pseudo-irreversible• inhibitors like GBR-12783. The potencies of these compounds 
against dopamine transport was comparable to their activities at the methylphenidate binding site. 
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Preliminary experiments suggest that 18d, the only derivative tested thus far against dopamine 
























. CH2C02H 6~c~ o~a . 
OH,NH(C;~nX o~NH(CH2)nX 0 ~b~ 
OCH~ OCH~ 
~ 
OH OCH2Ph OH 
OH OC~h OCH~h OC~Ph 
17 18a-d 
18a and 19a n=2, X=NH2 
18b and 19b n=3, X=NH2 
OH 
19a-d 
18c and 19c n=4, X=NH2 
18d and 19d n=2, X=NHCOCH2Br 
a. NaH/D~F, BnBr; b. KOH, EtOH/H20; c. B2H8/THF; d. SOCI2; e. ex. H2N(C:H2)nNH2/toluene; 
f. Pd/C/EtOH/H2• Note: derivatives 18d and 19d were made from 18a and 19a, respectively, with 
bromoacetyl bromide. 
In summary, the diamine derivatives 18a-18d and 19a bind with similar potency as dopamine. 
Interestingly, the bis-benzyl protected intermediates exhibited somewhat increased affinity, whereas 
the acylated derivative 18d is somewhat less potent. Compound 18a appears to be a 
psuedoirreversible inhibitor based on the inability to wash it out of tissue preparation under conditions 
that are effective for the GBR series. The effects of this psuedoirreversible compound on behavior will 
be tested shonly. At the present time it is not known if the bromoacetamide derivative 18d truly binds 
irreversibly or is just difficult to washout. 
6. General Pharmacology. The following information was gained: 
a. Similar to other stimulant binding, [3H]methylphenidate binding increases in phosphate buffer 
compared to Tris buffer. 
b. The stimulant drug amfonelic acid is a competitive inhibitor of the high affinity 
[
3H]methylphenidate binding site. 
c. The stimulant drug nomifensine has an IC:50 of 38 n~ at the [
3H]methylphenidate binding 
site. When the primary aromatic amine of nomifensine is convened to an isothiocyanate gr·oup the IC:50 
increased to 1360 n~; washout studies showed it was not binding irreversibly. 
d. When examined over 20 h, [3H]methylphenidate binding is severely reduced. Studies showed 
it was not due to· deterioration of the radioligand, suggesting that either the receptor itself is 
degrading, or an inhibitory compound is being elaborated. This differs from studies with [3H]GBR and 
[
3H]mazindol compounds, whose binding is relatively constant over 20 h. 
D. CHANGES IN THE SPECIFIC AIMS FOR NEW PROPOSAL (UNDERLINED CHANGES). 
The purpose of the proposed work is to synthesize and evaluate compounds which interact 
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with the stimulant binding site(s) on the dopamine transporter, with the aim of identifying compounds 
which are antagonists or partial agonists for the reinforcing and/or psychotogenic properties of 
cocaine. 
1. Derivatives of LR5182, a compound with some structural similarities to cocaine, but higher 
selectivity and affinity for the dopamine transporter, will be synthesized. 
2. Dual substrate. Several lines of evidence suggest that there may be more than one substrate 
and/or stimulant binding site per dopamine transport complex. Based on such a model, the effects of 
linking two dopamine molecules together and varying the distance of separation will be explored. 
3. A GBR derivative with two reactive groups in the same molecule will be synthesized, with 
the aim that they might span two binding sites (or subunits). 
4. New reversible GBR and Methylphenidate Analogs will be synthesized. The mutual inhibition 
of stimulant binding by GBR and methylphenidate with cocaine, suggests that derivatives of these 
stimulants may serve as antagonists or partial agonists for cocaine. 
5. The synthesis of the 3-epoxide derivative of GBR-1 2783 wil test whether epoxides caan be 
used to target sulfhydryl groups. 
6. The effect of the newly synthesized compounds on the dopamine transport complex will be 
determined by examining their ability to inhibit l3HJ-CFT. instead of l3Hlmethylphenidate binding. 
E. LIST ALL PUBLICATIONS SUBMITTED OR ACCEPTED THAT HAVE RESULTED FROM THIS 
PROJECT. 
Deutsch, H.M., M.M. Schweri, C.T. Culbertson, and L.H. Zalkow, 1992, Synthesis and pharmacology 
of irreversible affinity labels as potential cocaine antagonists. 1 . Aryl 1 ,4-dialkylpiperazines related to 
GBR-12783. Eur. J. Pharmacal., accepted pending revision. 
Schweri, M.M., A. Thurkauf, M.V. Mattson and K.C. Rice, K.C., 1992, Fourphit: a selective probe for 
the methylphenidate binding site on the dopamine transporter, J. Pharmacal. Exp. Ther. 261, 936. 
Abstracts/Presentations: 
Schweri, M.M., Thurkauf, A., and Rice, K.C.: Fourphit binds irreversibly to the stimulant recognition 
site on the dopamine transporter. Abstracts, Twentieth Annual Meeting Soc. Neuroscience 16: 687, 
Abstr. #287.4, 1990. 
Deutsch, H.M., Schweri, M.M., and Zalkow, L.H.: Cocaine antagonists. Synthesis of potential 
irreversible binding ligands for the methylphenidate binding site. Amer. Chern. Soc. Annual Meeting. 
1991. 
Schweri, M.M., Deutsch, H.M., Culbertson, C., and Zalkow, L.H.: A GBR-12783 derivative with 
potential as an irreversible cocaine antagonist. Abstracts, Seventy-fifth Annual Meeting, Fed. Amer. 
Soc. Expl. Bioi. 5: A 1590, Abstr. #7080, 1991. 
Schweri, M.M., de Costa, B.R., and Rice, K.C.: Fourphit inhibits cocaine-induced hyperactivity in rats. 
Abstracts, Twenty-first Annual Meeting Soc. Neuroscience, 17: Abst. #348.3, 1991. 
4. RESEARCH DESIGN AND METHODS 
The proposed research will be conducted as follows: (1) Continuation of presently funded 
work on the synthesis of affinity labels and simultaneous initiation of work on new synthetic targets; 
(2) Simultaneous start of in vitro biochemical testing; (3) Behavioral testing when appropriate 
compounds are available; (4) Ex vivo biochemical testing. The procedures to· be followed will be 
described under these headings in the text which follows. 
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